Vanessa A Olbrecht1,2, Lili Ding2,3, Kristie Spruance1, Monir Hossain4, Senthilkumar Sadhasivam1,2,5, Vidya Chidambaran1,2. 1. Departments of Anesthesia. 2. Pediatrics. 3. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center. 4. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital, Cincinnati, OH. 5. Riley Children's Hospital, Indianapolis, Indiana.
Abstract
OBJECTIVES: Since approval of intravenous acetaminophen (IV APAP), its use has become quite common without strong positive evidence. Our goal was to determine the effect of IV APAP on length of hospital stay (LOS) via mediation of opioid-related side effects in pediatric patients. MATERIALS AND METHODS: After Institutional Review Board approval, 114 adolescents undergoing posterior spinal fusion were prospectively recruited and managed postoperatively with patient-controlled analgesia and adjuvant therapy. Patients were divided into 2 groups based on the use of IV APAP: control (n=70) and treatment (n=44). Association of IV APAP use with opioid outcomes was analyzed using inverse probability of treatment weighting (IPTW)-adjusted propensity scores to balance the 2 groups for all significant covariates except postoperative opioid consumption. Mediation analysis was carried out for LOS with IV APAP as the independent variable and morphine consumption as the mediator. RESULTS: Oral intake was delayed by ∼1 day (P<0.001) and LOS was 0.6 days longer in the control group (P=0.044). After IPTW, time to oral intake remained significantly longer in the control group (P=0.014). The mediation model with IPTW revealed a significant negative association between IV APAP and morphine consumption (P<0.001), which significantly increased LOS (P<0.003). IV APAP had a significant opioid-sparing effect associated with shorter LOS. DISCUSSION: IV APAP hastens oral intake and is associated with decreased LOS in an adolescent surgery population likely through decreased opioid consumption. Through addition of IV APAP in this population, LOS may be decreased, an important implication in the setting of escalating health care costs.
OBJECTIVES: Since approval of intravenous acetaminophen (IV APAP), its use has become quite common without strong positive evidence. Our goal was to determine the effect of IV APAP on length of hospital stay (LOS) via mediation of opioid-related side effects in pediatric patients. MATERIALS AND METHODS: After Institutional Review Board approval, 114 adolescents undergoing posterior spinal fusion were prospectively recruited and managed postoperatively with patient-controlled analgesia and adjuvant therapy. Patients were divided into 2 groups based on the use of IV APAP: control (n=70) and treatment (n=44). Association of IV APAP use with opioid outcomes was analyzed using inverse probability of treatment weighting (IPTW)-adjusted propensity scores to balance the 2 groups for all significant covariates except postoperative opioid consumption. Mediation analysis was carried out for LOS with IV APAP as the independent variable and morphine consumption as the mediator. RESULTS: Oral intake was delayed by ∼1 day (P<0.001) and LOS was 0.6 days longer in the control group (P=0.044). After IPTW, time to oral intake remained significantly longer in the control group (P=0.014). The mediation model with IPTW revealed a significant negative association between IV APAP and morphine consumption (P<0.001), which significantly increased LOS (P<0.003). IV APAP had a significant opioid-sparing effect associated with shorter LOS. DISCUSSION: IV APAP hastens oral intake and is associated with decreased LOS in an adolescent surgery population likely through decreased opioid consumption. Through addition of IV APAP in this population, LOS may be decreased, an important implication in the setting of escalating health care costs.
Authors: Jonathan R Kamerlink; Martin Quirno; Joshua D Auerbach; Andrew H Milby; Lynne Windsor; Laura Dean; Joseph W Dryer; Thomas J Errico; Baron S Lonner Journal: J Bone Joint Surg Am Date: 2010-05 Impact factor: 5.284
Authors: Jennifer S Kelly; Yekaterina Opsha; Jennifer Costello; Daryl Schiller; Eric T Hola Journal: Pharmacotherapy Date: 2014-12 Impact factor: 4.705
Authors: Neeraj Sood; Peter J Huckfeldt; José J Escarce; David C Grabowski; Joseph P Newhouse Journal: Health Aff (Millwood) Date: 2011-09 Impact factor: 6.301
Authors: Shireesh Saurabh; Jessica K Smith; Mark Pedersen; Paul Jose; Peter Nau; Isaac Samuel Journal: Surg Obes Relat Dis Date: 2014-09-30 Impact factor: 4.734
Authors: Gary M Oderda; Qayyim Said; R Scott Evans; Gregory J Stoddard; Jim Lloyd; Kenneth Jackson; Dale Rublee; Matthew H Samore Journal: Ann Pharmacother Date: 2007-03-06 Impact factor: 3.154
Authors: Jian Ye; Karen Myung; Senthil Packiasabapathy; Jeffrey S Yu; Joseph E Jacobson; Stephanie C Whittaker; Peter Castelluccio; Meghan Drayton Jackson; Senthilkumar Sadhasivam Journal: Pediatr Qual Saf Date: 2020-07-27
Authors: Elaa M Mahdi; Shadassa Ourshalimian; David Darcy; Christopher J Russell; Lorraine I Kelley-Quon Journal: Surgery Date: 2021-05-10 Impact factor: 4.348